{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:59:02Z","timestamp":1781647142279,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The text reports the clinical case of a 61-year-old woman with a long history of generalized pruritus who was eventually diagnosed with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive T-cell lymphoproliferative disorder. At presentation, the patient had fever, skin lesions, lymphocytosis, thrombocytopenia, coagulation abnormalities, and marked splenomegaly without lymphadenopathy. Morphological, immunophenotypic, and histological analyses of peripheral blood and bone marrow revealed diffuse infiltration by mature T lymphocytes with strong TCL1 expression, and T-cell receptor gene rearrangement confirmed clonality, supporting the diagnosis of T-PLL. The patient initially received bendamustine chemotherapy, which failed to induce a response. Second-line treatment with the anti-CD52 monoclonal antibody alemtuzumab was subsequently initiated, but the disease proved refractory, with persistent bone marrow involvement, worsening cytopenias, disease progression, and clinical deterioration. As a result, alemtuzumab was discontinued and the patient was transitioned to palliative care. A particularly notable finding was the detection, by next-generation sequencing, of a pathogenic KRAS G12A mutation, which has not previously been reported in T-PLL. This mutation was identified incidentally using a myeloid-targeted NGS panel. The finding broadens the known mutational spectrum of T-PLL and suggests that activation of the RAS signaling pathway may represent an alternative oncogenic mechanism beyond the canonical TCL1 and JAK\u2013STAT pathways. We suggest that investigating for KRAS mutations in additional T-PLL cases may be beneficial to explore this pathogenetic pathway and could open new avenues for future targeted therapeutic strategies.<\/jats:p>","DOI":"10.1007\/s00277-026-06986-2","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:33:37Z","timestamp":1775712817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of T-prolymphocytic leukemia harboring RAS mutation"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-0481","authenticated-orcid":false,"given":"Salvatore","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7928-1610","authenticated-orcid":false,"given":"Giada","family":"Pacitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tirnetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mulargia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Angelitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-1226","authenticated-orcid":false,"given":"Andrea","family":"Corbingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Ortu La Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-8934","authenticated-orcid":false,"given":"Emiliano","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-5380","authenticated-orcid":false,"given":"Arianna","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"6986_CR1","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.3390\/ijms241512106","volume":"24","author":"M Gutierrez","year":"2023","unstructured":"Gutierrez M, Bladek P, Goksu B et al (2023) T-Cell prolymphocytic leukemia: diagnosis, pathogenesis, and treatment. Int J Mol Sci 24:12106. https:\/\/doi.org\/10.3390\/ijms241512106","journal-title":"Int J Mol Sci"},{"key":"6986_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2019000402","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber PB, Herling M, Bellido M et al (2019) Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 134:1132\u20131143. https:\/\/doi.org\/10.1182\/blood.2019000402","journal-title":"Blood"},{"key":"6986_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"6986_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","volume":"124","author":"MJ Kiel","year":"2014","unstructured":"Kiel MJ, Velusamy T, Rolland D et al (2014) Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124:1460\u20131472. https:\/\/doi.org\/10.1182\/blood-2014-03-559542","journal-title":"Blood"},{"key":"6986_CR5","doi-asserted-by":"publisher","first-page":"e0274463","DOI":"10.1371\/journal.pone.0274463","volume":"17","author":"N Mikhaylenko","year":"2022","unstructured":"Mikhaylenko N, Wahnschaffe L, Herling M et al (2022) Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia. PLoS ONE 17:e0274463. https:\/\/doi.org\/10.1371\/journal.pone.0274463","journal-title":"PLoS ONE"},{"key":"6986_CR6","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","volume":"12","author":"RM Carr","year":"2021","unstructured":"Carr RM, Vorobyev D, Lasho T et al (2021) RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun 12:2901. https:\/\/doi.org\/10.1038\/s41467-021-23186-w","journal-title":"Nat Commun"},{"key":"6986_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/10428194.2024.2441855","volume":"66","author":"F Zhang","year":"2025","unstructured":"Zhang F, Liu Y, Zhu Y et al (2025) Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia. Leuk Lymphoma 66:753\u2013763. https:\/\/doi.org\/10.1080\/10428194.2024.2441855","journal-title":"Leuk Lymphoma"},{"key":"6986_CR8","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MPD, Morin RD et al (2016) Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell\u2013derived lymphomas. Blood 128:1490\u20131502. https:\/\/doi.org\/10.1182\/blood-2016-02-698977","journal-title":"Blood"},{"key":"6986_CR9","doi-asserted-by":"publisher","unstructured":"Jones L, Rukhlenko O, Dias T et al (2025) A structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia bioRxiv [Preprint]. https:\/\/doi.org\/10.1101\/2025.04.29.651188","DOI":"10.1101\/2025.04.29.651188"},{"key":"6986_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","volume":"111","author":"M Herling","year":"2008","unstructured":"Herling M, Patel KA, Teitell MA et al (2008) High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111:328\u2013337","journal-title":"Blood"},{"issue":"24","key":"6986_CR11","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.3390\/jcm14248681","volume":"14","author":"S Perrone","year":"2025","unstructured":"Perrone S, Tresoldi C, Rigamonti S, Molica M, Zhdanovskaya N, Cicconi L (2025) How to read a next-generation sequencing report for aml and mds? what hematologists need to know. J Clin Med 14(24):8681. https:\/\/doi.org\/10.3390\/jcm14248681","journal-title":"J Clin Med"},{"key":"6986_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol 32:1101\u20131110. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.001","journal-title":"Ann Oncol"},{"key":"6986_CR13","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2025.0002","author":"S Kasper","year":"2025","unstructured":"Kasper S, Sebastian M (2025) The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: therapeutic principles and clinical results. Deutsches \u00c4rzteblatt international. https:\/\/doi.org\/10.3238\/arztebl.m2025.0002","journal-title":"Deutsches \u00c4rzteblatt international"},{"key":"6986_CR14","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A et al (2022) Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 28:2171\u20132182. https:\/\/doi.org\/10.1038\/s41591-022-02007-7","journal-title":"Nat Med"},{"key":"6986_CR15","doi-asserted-by":"publisher","first-page":"108889","DOI":"10.1016\/j.pharmthera.2025.108889","volume":"273","author":"N Hitchen","year":"2025","unstructured":"Hitchen N, Williams S, Desai J (2025) Recent advances in therapeutic targeting of the KRAS pathway in cancer. Pharmacol Ther 273:108889. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108889","journal-title":"Pharmacol Ther"},{"issue":"8","key":"6986_CR16","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1021\/acs.jmedchem.3c02403","volume":"67","author":"T Kirschner","year":"2024","unstructured":"Kirschner T, M\u00fcller MP, Rauh D, Targeting KRAS, Diversity (2024) Covalent modulation of G12X and beyond in cancer therapy. J Med Chem 67(8):6044\u20136051","journal-title":"J Med Chem"},{"key":"6986_CR17","doi-asserted-by":"publisher","unstructured":"Arani N, Rausch CR, Geppner A et al (2025) Cladribine and venetoclax combined with alemtuzumab in patients with relapsed\/refractory T-cell prolymphocytic leukemia. Leuk Lymphoma 1\u20135. https:\/\/doi.org\/10.1080\/10428194.2025.2566318","DOI":"10.1080\/10428194.2025.2566318"},{"key":"6986_CR18","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.27972","volume":"119","author":"G Hopfinger","year":"2013","unstructured":"Hopfinger G, Busch R, Pflug N et al (2013) Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer 119:2258\u20132267. https:\/\/doi.org\/10.1002\/cncr.27972","journal-title":"Cancer"},{"key":"6986_CR19","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1007\/s00277-025-06344-8","volume":"104","author":"N An","year":"2025","unstructured":"An N, Bian K, Li C (2025) Alemtuzumab for haematological malignancies. Ann Hematol 104:2593\u20132603. https:\/\/doi.org\/10.1007\/s00277-025-06344-8","journal-title":"Ann Hematol"},{"key":"6986_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.20517\/cdr.2022.130","volume":"6","author":"S Perrone","year":"2023","unstructured":"Perrone S, Ottone T, Zhdanovskaya N, Molica M (2023) How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication. Cancer Drug Resist 6:223\u2013238. https:\/\/doi.org\/10.20517\/cdr.2022.130","journal-title":"Cancer Drug Resist"},{"key":"6986_CR21","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood.2024027171","volume":"145","author":"MF Pohly","year":"2025","unstructured":"Pohly MF, Putzker K, Scheinost S et al (2025) IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening. Blood 145:2336\u20132352. https:\/\/doi.org\/10.1182\/blood.2024027171","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06986-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:39:30Z","timestamp":1781645970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6986"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06986-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was done in accordance to Helsinki declaration. All information was anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Written consent was given by relatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}